Histologically or cytologically confirmed stage IIIB/IV lung cancer with EGFR mutation
Progressed after platinum-based chemotherapy
The last anti-tumor therapy before entering this study must be gefitinib, erlotinib or icotinib, and the duration for tumor response must be no less than 4 months, or the duration for stable disease must be no less than 6 months
With a measurable disease with conventional CT) according to RECIST Criteria
WHO performance status(PS)\<= 2
N\>=1.5×109/L, Plt\>=1.0×109/L,Hb\>=9g/dL; AST\&ALT should \<2.5ULN(without liver metastasis) or \<5ULN(with liver metastasis).TBIL\<=1.5ULN.
Signed and dated informed consent before the start of specific protocol procedures.
You may not be if
Allergic to icotinib or arsenic trioxide.
Patients with metastatic brain tumors with symptoms.
Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.
Clareo Health | Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
